Global Dementia Legacy Event: Mr. Dirk Pilat
•Transferir como PPTX, PDF•
1 gostou•971 visualizações
Session 3: To explore ways in which we can increase investment in innovation. In part 1 panellists will highlight ways in which they are seeking to tackle barriers and find solutions, including through big data, patient involvement in clinical trials and social investment. Mr. Dirk Pilat, Deputy Director, Directorate for Science, Technology and Industry, OECD & Technical Advisor to the World Dementia Council
Recomendados
Recomendados
Mais conteúdo relacionado
Mais de Department of Health
Mais de Department of Health (20)
Último
Último (20)
Global Dementia Legacy Event: Mr. Dirk Pilat
- 1. 1 Dementia – the Innovation Challenge Innovation in Dementia Care Innovation and Investment Innovation and Big data - Prevention strategies - Incentives for better quality care - Dementia-friendly communities - Coordination of health and care services - Challenges: little scaling and cross-country learning - Complex area for investors - multiple actors, high risk - New financing models and public-private partnerships - Improve environment for innovation to unlock investment - Powerful resource for new models of care, discovery, collaboration - Growing availability of data, but also conceptual change - Challenges: data access, international cooperation, sustainability, … Source: WHO, Global Health and Aging, 2011 A Global Challenge
Notas do Editor
- Age-related diseases, in particular Alzheimer’s disease severely impact the life of individuals, public health systems, national prosperity, productivity and economic growth. The full potential of the emerging biomedical technologies to fight dementia will become available through co-ordinated and inclusive policies. Governments can provide the right policies and long-term strategies to support the translation of biomedical research findings into health innovation. This requires adequate financial, technical and human resources. Dementia represents a significant challenge for public health systems worldwide. The ageing of society, and increasing prevalence of Alzheimer’s disease in particular, drive the demand for further research into innovative therapies and highlight the need for a supportive policy environment. The case of Alzheimer’s disease illustrates the challenges of dementia research throughout the entire health innovation cycle. Alzheimer’s disease has been considered as relevant to characterise the main (policy) issues associated with innovation in biomedicine for healthy ageing.